CNR1 and diabetes mellitus: Several studies have demonstrated that intrathecal delivery of synthetic cannabinoid CB1 and CB2 receptor agonists reduces allodynia in a range of neuropathic pain models of nerve injury, chemotherapeutic drugs, diabetes and cancer [22,23,24,25,26,27,28,29,30,31,32,33,34].